SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“Save the date | 4th Definitive Trial webinar
Neoadjuvant strategies are reshaping surgical decision-making in HER2-positive breast cancer. But how can treatment pathways be truly optimised in daily clinical practice?
On 02 February 2026, leading experts will explore current evidence-based standards of care, key factors in tailoring neoadjuvant therapy, and the evolving role of surgery following systemic treatment, offering practical insights for multidisciplinary teams involved in HER2+ breast cancer management.
More information and registration.
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
More posts featuring SPCC on OncoDaily.